NASDAQ:IMUX
Immunic, Inc.
Immunic, Inc. reported net income of −$97.2M in fiscal 2025. Free cash flow was −$86.0M, and the diluted share count rose 55.4%.Summary generated from Immunic, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−1653.1%
Debt / equityn/a
Free cash flow−$86.0M
FCF marginn/a
Share count change+55.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −92 | −119 | −99 | −98 | −103 |
| Net income | −93 | −120 | −94 | −101 | −97 |
| Free cash flow | −83 | −65 | −71 | −85 | −86 |
Recent filings
- 4Insider transaction report
Sep 18, 2026 - 4Insider transaction report
Sep 18, 2026 - 8-KDirector or officer change
Sep 11, 2026 - 8-KRegulation FD disclosure
Sep 9, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KRegulation FD disclosure
Jul 14, 2026 - 8-KDirector or officer change
Jul 6, 2026